Adam Mendelsohn

Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company. During his time with Nano Precision Medical, Dr. Mendelsohn has helped raise over $20M in funding from individuals, family offices, and from a large pharmaceutical company. Dr. Mendelsohn has also helped grow the company to more than 27 employees, successfully negotiated intellectual property transactions, overseen the company’s preclinical development program including interactions with the FDA, and recruited key advisors and leadership to support the company’s operations and development efforts.
Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.
Dr. Mendelsohn currently is a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, and a board member of the Maestro Foundation.